Condition

Recurrent Small Cell Lung Cancer

ClinicalTrials.gov condition label

Clinical trials29

Recruiting2

Common interventions25

Lead sponsors shown12

Clinical trials

29 shown

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · 2026-10-12

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCNCT06681220 · 2026-02-23

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerNCT05162196 · 2022-06-01

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCNCT04610658 · 2020-11-23

Anlotinib in Treatment of Recurrent Small Cell Lung CancerNCT03732846 · 2018-11-01

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer PatientsNCT01999881 · 2013-12-01

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung CancerNCT01931787 · 2013-10-01

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · 2013-09-24

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung CancerNCT01901653 · 2013-07-01

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung CancerNCT01803269 · 2013-01-16

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the BodyNCT01325753 · 2011-03-01

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung CancerNCT01457469 · 2011-01-01

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsNCT01155258 · 2010-06-01

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00828139 · 2009-05-01

R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung CancerNCT00773955 · 2008-11-01

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung CancerNCT00528645 · 2007-11-01

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid TumorsNCT00521144 · 2007-08-01

Dasatinib in Treating Patients With Relapsed Small Cell Lung CancerNCT00470054 · 2007-04-01

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung CancerNCT00182689 · 2005-07-01

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung CancerNCT00098956 · 2005-01-01

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal CancerNCT00088933 · 2004-06-01

Romidepsin in Treating Patients With Relapsed Small Cell Lung CancerNCT00086827 · 2004-05-01

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line ChemotherapyNCT00084487 · 2004-04-01

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung CancerNCT00052949 · 2003-05-01

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung CancerNCT00042978 · 2003-04-01

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsNCT00028535 · 2001-11-01

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)NCT00168922 · 2001-02-01

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerNCT00020202 · 2000-06-01

Common interventions

Leading sponsors

National Cancer Institute (NCI)16 Wake Forest University Health Sciences3 Charite University, Berlin, Germany1 H. Lee Moffitt Cancer Center and Research Institute1 Peking University Cancer Hospital & Institute1 Stemcentrx1 University of Chicago1 University of Colorado, Denver1 University of Southern California1 University of Wisconsin, Madison1 VA Office of Research and Development1 Wuhan University1

Trial status mix

COMPLETED19

TERMINATED4

UNKNOWN3

RECRUITING2

WITHDRAWN1

Phase mix

PHASE219

PHASE111

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.